专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2007136465A3 COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS 审中-公开
标题翻译： FGF受体激酶抑制剂的组合物和方法
公开(公告)号：WO2007136465A3
公开(公告)日：2009-01-22
申请号：PCT/US2007008699
申请日：2007-04-06
申请人： IRM LLC , REN PINGDA , ZHANG GUOBAO , YOU SHULI , SIM TAEBO , GRAY NATHANAEL , XIE YONGPING , WANG XING , HE YUN
发明人： REN PINGDA , ZHANG GUOBAO , YOU SHULI , SIM TAEBO , GRAY NATHANAEL , XIE YONGPING , WANG XING , HE YUN
IPC分类号： A61K31/5355 , A61K31/497 , A61K31/513 , A61K31/53 , A61P35/00 , C07D253/065 , C07D413/12 , C07D413/14 , C07D471/04 , C07D487/04
CPC分类号： C07D487/04 , C07D471/04
摘要： Described are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent disease or disordered associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activity of kinases such as AbI, ALK, AMPK, Aurora, AxI, Bcr-Abl, BIK, Bmx, BRK, BTK, c-Kit, CSK, cSrc, CDKl, CHK2, CKl, CK2, CaMKII, CaMKIV, DYRK2, EGFR, EphBl, FES, FGFRl, FGFR2, FGFR3, Fltl, FlO, FMS, Fyn, GSK3ß, IGF lR, IKKa DCKß, IR, IRAK4, ITK, JAK2, JAK3, JNKlal, JNK2a, KDR, Lck, LYN, MAPKl, MAPKAP-K2, MEKl, MET, MKK4, MKK6, MST2, NEK2, NLK, p70S6K, PAK2, PDGFR, PDGFRa, PDKl, Pim-2, Plk3, PKA, PKBa, PKCa PKCtheta, PKD2, c-Raf, RET, ROCK-I1 ROCK-II, Ron, Ros, Rskl, SAPK2a, SAPK2b, SAPK3, SAPK4, SGK, SIK, Syk, Tie2, TrkB, WNK3, and ZAP-70.
摘要翻译：描述的是化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或紊乱的方法，特别是涉及激酶例如AbI，ALK，AMPK，Aurora的异常活性的疾病或病症，Axi，Bcr-Abl，BIK，Bmx，BRK，BTK，c-Kit，CSK，cSrc，CDK1，CHK2，CK1，CK2，CaMKII，CaMKIV，DYRK2，EGFR，EphB1，FES，FGFR1，FGFR2，FGFR3，Flt1 ，MKIA，MAPKAP-K2，MEK1，MET，MKK4，MKK6，MST2，MKIA，MAPKAP-K2，MEK1，MET，MKK4，MKK6，，NEK2，NLK，p70S6K，PAK2，PDGFR，PDGFRa，PDK1，Pim-2，Plk3，PKA，PKBa，PKCaPKCθ，PKD2，c-Raf，RET，ROCK-I1 ROCK-II，Ron，Ros，Rskl，SAPK2a ，SAPK2b，SAPK3，SAPK4，SGK，SIK，Syk，Tie2，TrkB，WNK3和ZAP-70。

12. 发明申请

WO2008112695A2 PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF 审中-公开
标题翻译：蛋白激酶抑制剂及其使用方法
公开(公告)号：WO2008112695A2
公开(公告)日：2008-09-18
申请号：PCT/US2008056523
申请日：2008-03-11
申请人： IRM LLC , REN PINGDA , WANG XIA , HE YUN , OKRAM BARUN , WANG XIAODONG , ZHANG GUOBAO , LIU ZUOSHENG , LIU YI , ALBAUGH PAMELA A
发明人： REN PINGDA , WANG XIA , HE YUN , OKRAM BARUN , WANG XIAODONG , ZHANG GUOBAO , LIU ZUOSHENG , LIU YI , ALBAUGH PAMELA A
CPC分类号： C07D487/04 , C07D471/14
摘要： The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of Alk, Abl, Aurora-A, B-raf, Bcr-Abl, BRK, Blk, Bmx, cKit, c-RAF, cSRC, CSK, FLT1, Fms, Fyn, JAK2, KDR, Lck, Lyn, PDGFRa, PDGFRß, PKCa, p38 (p38 MAP kinase, SAPK2a), Src, SIK, Syk, Tie2 and TrkB kinases.
摘要翻译：本发明提供了可用作蛋白激酶抑制剂的化合物及其药物组合物，以及使用这些化合物治疗，改善或预防与异常或失调的激酶活性相关的病症的方法。在一些实施方案中，本发明提供了使用这些化合物治疗，改善或预防涉及Alk，Abl，Aurora-A，B-raf，Bcr-Abl，BRK，Blk，Bmx，cKit异常激活的疾病或病症的方法， c-RAF，cSRC，CSK，FLT1，Fms，Fyn，JAK2，KDR，Lck，Lyn，PDGFRa，PDGFRβ，PKCa，p38（p38 MAP激酶，SAPK2a），Src，SIK，Syk，Tie2和TrkB激酶。

13. 发明申请

WO2007134259A3 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS 审中-公开
标题翻译：作为蛋白激酶抑制剂的化合物和组合物
公开(公告)号：WO2007134259A3
公开(公告)日：2008-01-17
申请号：PCT/US2007068819
申请日：2007-05-11
申请人： IRM LLC , REN PINGDA , WU BAOGEN , ZHANG GUOBAO , XIE YONGPING , OKRAM BARUN , NIKULIN VICTOR , WANG XIA , CHOI HA-SOON
发明人： REN PINGDA , WU BAOGEN , ZHANG GUOBAO , XIE YONGPING , OKRAM BARUN , NIKULIN VICTOR , WANG XIA , CHOI HA-SOON
IPC分类号： C07D471/14 , A61K31/4375
CPC分类号： C07D471/14
摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the AbI, Bcr-Abl, Bcr-Abl(T315I), ALK5BLK, BMX, BRK, C-kit, c-RAF, CSK, c-SRC, EGFR, Fes, FGFR3, Flt3, Fms, Fyn, IGF-IR, IR, JAK(2), JAK(3), KDR, Lck, NLK, p70S6K, PDGFRa, Ros, SAPK2a, SGK, SIK, Syk, Tie2 and TrkB kinases.
摘要翻译：本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法，特别是涉及AbI，Bcr-Abl异常活化的疾病或病症，Bcr-Abl（T315I），ALK5BLK，BMX，BRK，C-kit，c-RAF，CSK，c-SRC，EGFR，Fes，FGFR3，Flt3，Fms，Fyn，IGF-IR，IR，JAK（2），JAK（3），KDR，Lck，NLK，p70S6K，PDGFRa，Ros，SAPK2a，SGK，SIK，Syk，Tie2和TrkB激酶。

14. 发明申请

WO0107013A9 THIOAMIDE MOIETY-CONTAINING POLYMER DRUG CONJUGATES 审中-公开
标题翻译：含有酰胺的含MOIETY聚合物药物的药物
公开(公告)号：WO0107013A9
公开(公告)日：2002-11-14
申请号：PCT/US0020090
申请日：2000-07-24
申请人： UNIV NEW JERSEY MED , STEIN STANLEY , ZHANG GUOBAO , QIU BO
发明人： STEIN STANLEY , ZHANG GUOBAO , QIU BO
IPC分类号： A61K47/48
CPC分类号： A61K47/60
摘要： This invention pertains to disulfide-linked conjugates of therapeutic agents containing at least one thioamide group with polymer comprising at least one thiol group, so as to provide a controlled release pharmaceutical composition for administration to animals for the prophylaxis or treatment of various conditions or diseases. The therapeutic agent conjugate may comprise an inactive or weakly active prodrug form which may be converted into the original therapeutic compound by the natural action of reducing agents in vivo . The composition may comprise a mixture of polymers each with a different thioamide-containing agent attached, or a polymer conjugated with a mixture of thioamide-containing agents. Modified properties of the therapeutic compound potentially provided by the polymer itself, as well as by other compounds also appended to the polymer, include but are not limited to greater water solubility, longer in vivo half-life (due to larger size of the conjugate), slower release from a sustained-release depot (due to larger size of the conjugate), better oral bioavailability and tissue-specific targeting.
摘要翻译：本发明涉及含有至少一种硫代酰胺基团的治疗剂与包含至少一种硫醇基团的聚合物的二硫键连接的缀合物，以提供用于预防或治疗各种病症或疾病的用于给予动物的控释药物组合物。治疗剂缀合物可以包含无活性或弱活性的前药形式，其可以通过体内还原剂的天然作用转化为原始治疗化合物。组合物可以包含各自与不同含硫代酰胺的试剂连接的聚合物的混合物，或与含硫代酰胺的试剂的混合物缀合的聚合物。由聚合物本身可能提供的治疗化合物以及也附加到聚合物上的其它化合物的治疗化合物的改进性质包括但不限于更大的水溶性，更长的体内半衰期（由于缀合物的较大尺寸）缓释片段缓慢释放（由于缀合物尺寸较大），更好的口服生物利用度和组织特异性靶向。

15. 发明申请

WO0107013A2 MATERIALS AND PROCESSES FOR CONTROLLED RELEASE OF THIOAMIDE MOIETY-CONTAINING THERAPEUTIC AGENTS BY LINKING TO THIOL-CONTAINING POLYMERS 审中-公开
标题翻译：通过连接含THIOL的聚合物控制释放含有硫氧化物的含药物治疗药物的材料和方法
公开(公告)号：WO0107013A2
公开(公告)日：2001-02-01
申请号：PCT/US0020090
申请日：2000-07-24
申请人： UNIV NEW JERSEY MED , STEIN STANLEY , ZHANG GUOBAO , QIU BO
发明人： STEIN STANLEY , ZHANG GUOBAO , QIU BO
IPC分类号： A61K47/48 , A61K9/00
CPC分类号： A61K47/60
摘要： This invention pertains to disulfide-linked conjugates of therapeutic agents containing at least one thioamide group with polymer comprising at least one thiol group, so as to provide a controlled release pharmaceutical composition for administration to animals for the prophylaxis or treatment of various conditions or diseases. The therapeutic agent conjugate may comprise an inactive or weakly active prodrug form which may be converted into the original therapeutic compound by the natural action of reducing agents in vivo . The composition may comprise a mixture of polymers each with a different thioamide-containing agent attached, or a polymer conjugated with a mixture of thioamide-containing agents. Modified properties of the therapeutic compound potentially provided by the polymer itself, as well as by other compounds also appended to the polymer, include but are not limited to greater water solubility, longer in vivo half-life (due to larger size of the conjugate), slower release from a sustained-release depot (due to larger size of the conjugate), better oral bioavailability and tissue-specific targeting.
摘要翻译：本发明涉及含有至少一种硫代酰胺基团的治疗剂与包含至少一种硫醇基团的聚合物的二硫键连接的缀合物，以提供用于预防或治疗各种病症或疾病的用于给予动物的控释药物组合物。治疗剂缀合物可以包含无活性或弱活性的前药形式，其可以通过体内还原剂的天然作用转化为原始治疗化合物。组合物可以包含各自与不同含硫代酰胺的试剂连接的聚合物的混合物，或与含硫代酰胺的试剂的混合物缀合的聚合物。由聚合物本身可能提供的治疗化合物以及也附加到聚合物上的其它化合物的治疗化合物的改进性质包括但不限于更大的水溶性，更长的体内半衰期（由于到更大尺寸的缀合物），缓释片段的缓慢释放（由于缀合物的较大尺寸），更好的口服生物利用度和组织特异性靶向。

16. 发明公开

EP1858521A4 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS 审中-公开
公开(公告)号：EP1858521A4
公开(公告)日：2011-07-06
申请号：EP06737854
申请日：2006-03-10
申请人： IRM LLC
发明人： REN PINGDA , GRAY NATHANAEL S , WANG XIA , ZHANG GUOBAO
IPC分类号： A61K31/519 , A61K31/52 , A61P35/00 , C07D487/04
CPC分类号： C07D487/04 , A61K31/519 , A61K31/52

17. 发明专利

ES2375151T3 DERIVADOS DE BENCIMIDAZOL SUSTITUIDOS CON PIRIMIDINA COMO INHIBIDORES DE PROTEINA CINASA. 未知
公开(公告)号：ES2375151T3
公开(公告)日：2012-02-27
申请号：ES06774386
申请日：2006-06-30
申请人： IRM LLC A DELWARE LTD LIABILITY COMPANY , IRM LLC
发明人： ZHANG GUOBAO , REN PINGDA , WANG XIA , GRAY NATHANAEL S , SIM TAEBO
IPC分类号： C07D403/14 , A61K31/495 , A61P35/00 , C07D401/14 , C07D403/04 , C07D409/14 , C07D413/14
摘要： Compuesto de fórmula Ia: y sales farmacéuticamente aceptables del mismo, en la que: p se selecciona de 0 y 1; n es 1-3; q es 1; R5 se selecciona de hidrógeno, alquilo C1-6, -XNR7R8, aril C6-10-alquilo C0-4, heteroaril C1-10-alquilo C0-4, cicloalquil C3- 10-alquilo C0-4 y heterocicloalquil C3-10-alquilo C0-4; R7 y R8 se seleccionan independientemente de hidrógeno y alquilo C1-4; y R6 se selecciona de hidrógeno y alquilo C1-6; o R5 y R6 junto con el nitrógeno al que R5 y R6 están ambos unidos forman heteroarilo C1-10 o heterocicloalquilo C3-8; en el que cualquier arilo, heteroarilo, cicloalquilo y heterocicloalquilo de R5 o la combinación de R5 y R6 puede estar opcionalmente sustituido con de 1 a 3 radicales independientemente seleccionados de halo, nitro, ciano, hidroxilo, alquilo C1-6, alcoxilo C1-6, alquilo sustituido con halo, alcoxilo sustituido con halo, -XNR7R8, XOR7, -XNR7S(O)2R8, - XNR7S(O)R8, -XNR7SR8, -XC(O)NR7R8, -XC(O)NR7XNR7R8, -XNR7C(O)NR7R8, XNR7XNR7R8, -XNR7XOR7, -XNR7C (=NR7)NR7R8, -XS(O)2R9, -XNR7C(O)R8, -XNR7C(O)R9, -XR9, XC( O)OR8, -XS(O)2NR7R8, -XS(O)NR7R8 y - XSNR7R8; en el que X es un enlace o alquileno C1-4; R7 y R8 se seleccionan independientemente de hidrógeno y alquilo C1-4; y R9 se selecciona de heterocicloalquilo C3-10 y heteroarilo C1-10; en el que dicho heterocicloalquilo o heteroarilo de R9 está opcionalmente sustituido con un radical seleccionado de alquilo C1-4, -XNR7XNR7R7, XNR7XOR7 y -XOR7; en el que X es un enlace o alquileno C1-4 opcionalmente sustituido con de 1 a 2 radicales alquilo C1-6 y R7 se selecciona de hidrógeno, y alquilo C1-4; R10 se selecciona de hidrógeno y alquilo C1-6; R15 se selecciona de halo, nitro, ciano, hidroxilo, alquilo C1-6, alcoxilo C1-6, alquilo sustituido con halo y alcoxilo sustituido con halo; y R16 se selecciona de halo, metoxilo, nitro, -NR12C(O)R13, -OR13, -C(O)NR12R12, -NR12R12, NR12C( O)NR12R13, - C(O)OR12, -C(O)NR12R13, -NR12S(O)0-2R13 y -S(O)0-2NR12R13; en el que cada R12 se selecciona independientemente de hidrógeno y alquilo C1-6; R13 se selecciona de arilo C6-10, heteroarilo C1-10, cicloalquilo C3-10 y heterocicloalquilo C3- 10; en el que cualquier alquileno de un sustituyente R13 puede tener un metileno sustituido por O o NR7; en el que cualquier arilo, heteroarilo, cicloalquilo o heterocicloalquilo de R13 está opcionalmente sustituido con de 1 a 3 radicales independientemente seleccionados de halo, alquilo C1-6, alquilo C1-6 sustituido con halo, alcoxilo C1-6, alcoxilo C1-6 sustituido con halo, -XNR7R8, aril C6-10-alquilo C0-4, heteroaril C1-10-alquilo C0-4, cicloalquil C3-10-alquilo C0-4, heterocicloalquil C3-10-alcoxilo C0-4 y heterocicloalquil C3-10-alquilo C0-4; en el que X, R7 y R8 son tal como se describió anteriormente y en el que cualquier sustituyente arilo, heteroarilo, cicloalquilo o heterocicloalquilo de R13 está además opcionalmente sustituido con de 1 a 3 radicales independientemente seleccionados de halo, alquilo C1- 6, alquilo C1-6 sustituido con halo, alquilo C1-6 sustituido con hidroxilo, NR7R8, alcoxilo C1-6, heterocicloalquilo C3-10 y alcoxilo C1-6 sustituido con halo en el que los grupos cicloalquilo son conjuntos de anillos saturados o insaturados, monocíclicos, bicíclicos condensados o policíclicos en puente, y los grupos heterocicloalquilo son grupos cicloalquilo con uno o más de los átomos de carbono de anillo sustituido por un resto seleccionado de -O-, -N=, -NR-, -C(O)-, -S- , -S(O)- o S(O)2- en el que R es H, alquilo C1-4 o un grupo protector de nitrógeno.

18. 发明公开

EP1656378A4 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF RECEPTOR TYROSINE KINASE ACTIVITY 审中-公开
标题翻译：化合物和组合物受体酪氨酸激酶活性的抑制剂
公开(公告)号：EP1656378A4
公开(公告)日：2011-05-11
申请号：EP04781114
申请日：2004-08-13
申请人： IRM LLC
发明人： CHENG DAI , DING QIANG , HAN DONG , GRAY NATHANAEL SCHIANDER , ZHANG GUOBAO
IPC分类号： C07D473/40 , A61K31/52 , A61K31/522 , A61P9/10 , A61P11/06 , A61P17/06 , A61P35/00 , A61P35/02 , C07D473/04 , C07D473/16 , C07D473/18 , C07D473/34
CPC分类号： C07D473/16 , C07D473/18 , C07D473/34 , C07D473/40

19. 发明公开

EP2018167A4 COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS 审中-公开
标题翻译： ZUSAMMENSETZUNGEN UND VERFAHRENFÜRFGF-REZEPTOR-KINASE-HEMMER
公开(公告)号：EP2018167A4
公开(公告)日：2010-07-14
申请号：EP07755084
申请日：2007-04-06
申请人： IRM LLC
发明人： REN PINGDA , ZHANG GUOBAO , YOU SHULI , SIM TAEBO , GRAY NATHANAEL , XIE YONGPING , WANG XING , HE YUN
IPC分类号： A61K31/5355 , A61K31/497 , A61K31/513 , A61K31/53 , A61P35/00 , C07D253/065 , C07D413/12 , C07D413/14 , C07D471/04 , C07D487/04
CPC分类号： C07D487/04 , C07D471/04

20. 发明公开

EP1758892A4 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS 有权
公开(公告)号：EP1758892A4
公开(公告)日：2010-07-28
申请号：EP05759571
申请日：2005-06-09
申请人： IRM LLC
发明人： REN PINGDA , WANG XIA , ZHANG GUOBAO , DING QIANG , YOU SHULI , ZHANG QIONG , CHOPIUK GREG , ALBAUGH PAMELA A , SIM TAEBO , GRAY NATHANAEL SCHIANDER
IPC分类号： C07D403/04 , A61K31/4178 , C07D401/14 , C07D403/14 , C07D405/14 , C07D417/14
CPC分类号： C07D403/04 , C07D401/14 , C07D403/14 , C07D405/14 , C07D417/14

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式